Could a peptide help control obesity and blood pressure?
NCT ID NCT02646475
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study aims to see if a natural substance called angiotensin-(1-7) can improve how the body uses insulin in people with obesity, insulin resistance, and high blood pressure. About 26 adults aged 18-60 will receive the peptide or a placebo infusion, and researchers will measure changes in insulin sensitivity, blood pressure, and heart function. The goal is to understand if this approach could lead to new treatments for metabolic diseases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Squeeze away hypertension? handgrip device put to the test
- Blood pressure cuffs and health classes: a new approach to close a heart health gap
- AI tailors lifestyle tips to tackle high blood pressure
- A fiber supplement may help perimenopausal women — a trial puts it to the test
- Could a simple clinic Check-In change catch hidden high blood pressure and diabetes?
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control